ZA200205238B - The use of mirtazapine for the treatment of sleep disorders. - Google Patents
The use of mirtazapine for the treatment of sleep disorders. Download PDFInfo
- Publication number
- ZA200205238B ZA200205238B ZA200205238A ZA200205238A ZA200205238B ZA 200205238 B ZA200205238 B ZA 200205238B ZA 200205238 A ZA200205238 A ZA 200205238A ZA 200205238 A ZA200205238 A ZA 200205238A ZA 200205238 B ZA200205238 B ZA 200205238B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- mirtazapine
- sleep
- composition
- dose
- Prior art date
Links
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title claims description 42
- 229960001785 mirtazapine Drugs 0.000 title claims description 42
- 208000019116 sleep disease Diseases 0.000 title claims description 29
- 239000003814 drug Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 13
- 208000020685 sleep-wake disease Diseases 0.000 claims description 11
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 8
- 206010022437 insomnia Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000005022 packaging material Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims 6
- 230000007958 sleep Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010068932 Terminal insomnia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000036421 sense of balance Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00200499 | 2000-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200205238B true ZA200205238B (en) | 2003-09-29 |
Family
ID=8171013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200205238A ZA200205238B (en) | 2000-02-11 | 2002-06-28 | The use of mirtazapine for the treatment of sleep disorders. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6933293B2 (es) |
| EP (4) | EP1257278B1 (es) |
| JP (1) | JP5039994B2 (es) |
| KR (1) | KR20020069371A (es) |
| CN (2) | CN101229170A (es) |
| AR (1) | AR027394A1 (es) |
| AT (1) | ATE317261T1 (es) |
| AU (1) | AU780439B2 (es) |
| BR (1) | BR0108261A (es) |
| CA (1) | CA2396209C (es) |
| CO (1) | CO5271706A1 (es) |
| CZ (1) | CZ302368B6 (es) |
| DE (1) | DE60117122T2 (es) |
| DK (1) | DK1257278T3 (es) |
| ES (1) | ES2258071T3 (es) |
| HK (1) | HK1049122B (es) |
| HU (1) | HUP0204391A3 (es) |
| IL (2) | IL150290A0 (es) |
| NO (1) | NO328007B1 (es) |
| PE (1) | PE20011080A1 (es) |
| PL (1) | PL206073B1 (es) |
| RU (1) | RU2270680C2 (es) |
| SK (1) | SK287396B6 (es) |
| WO (1) | WO2001058453A1 (es) |
| ZA (1) | ZA200205238B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040152055A1 (en) * | 2003-01-30 | 2004-08-05 | Gliessner Michael J.G. | Video based language learning system |
| UA83666C2 (ru) | 2003-07-10 | 2008-08-11 | Н.В. Органон | Способ получения энантиомерно чистого миртазапина |
| WO2005051349A2 (en) * | 2003-11-25 | 2005-06-09 | Aurobindo Pharma Ltd. | Pharmaceutical compositions of mirtazapine |
| GB0417558D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Novel combination therapy |
| US20080112893A1 (en) * | 2004-10-14 | 2008-05-15 | Arai Jun-Ichiro | Atmosphere Modifying Method and Spray Agent and Spray Device Used in the Same |
| JP2006137748A (ja) * | 2004-10-14 | 2006-06-01 | Daikin Ind Ltd | 雰囲気改変方法、並びに、それに用いられる噴霧剤及び噴霧装置 |
| JP2007284363A (ja) * | 2006-04-13 | 2007-11-01 | Daikin Ind Ltd | 噴霧剤 |
| AR066005A1 (es) | 2007-04-11 | 2009-07-15 | Organon Nv | Un metodo para la preparacion de un enantiomero de una benzazepina tetraciclica |
| PL3261645T3 (pl) | 2015-02-27 | 2021-12-06 | Dechra Limited | Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów |
| CN111053735A (zh) * | 2020-02-25 | 2020-04-24 | 上海阶平医院管理有限公司 | 一种治疗失眠的冷敷凝胶 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| EP0813873B1 (en) | 1996-06-19 | 2002-02-13 | Akzo Nobel N.V. | Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| PT1030667E (pt) * | 1997-11-14 | 2005-06-30 | Akzo Nobel Nv | Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono |
-
2001
- 2001-02-06 CN CNA2008100056868A patent/CN101229170A/zh active Pending
- 2001-02-06 EP EP01902410A patent/EP1257278B1/en not_active Expired - Lifetime
- 2001-02-06 EP EP05109549A patent/EP1658850A1/en not_active Withdrawn
- 2001-02-06 JP JP2001557563A patent/JP5039994B2/ja not_active Expired - Lifetime
- 2001-02-06 US US10/203,232 patent/US6933293B2/en not_active Expired - Lifetime
- 2001-02-06 PL PL356721A patent/PL206073B1/pl not_active IP Right Cessation
- 2001-02-06 CN CN01803934A patent/CN1395487A/zh active Pending
- 2001-02-06 ES ES01902410T patent/ES2258071T3/es not_active Expired - Lifetime
- 2001-02-06 AU AU30247/01A patent/AU780439B2/en not_active Expired
- 2001-02-06 EP EP10178745A patent/EP2283840A1/en not_active Withdrawn
- 2001-02-06 IL IL15029001A patent/IL150290A0/xx unknown
- 2001-02-06 KR KR1020027009536A patent/KR20020069371A/ko not_active Application Discontinuation
- 2001-02-06 HU HU0204391A patent/HUP0204391A3/hu unknown
- 2001-02-06 DE DE60117122T patent/DE60117122T2/de not_active Expired - Lifetime
- 2001-02-06 DK DK01902410T patent/DK1257278T3/da active
- 2001-02-06 BR BR0108261-2A patent/BR0108261A/pt not_active Application Discontinuation
- 2001-02-06 EP EP05109547A patent/EP1656937A1/en not_active Ceased
- 2001-02-06 WO PCT/EP2001/001221 patent/WO2001058453A1/en active IP Right Grant
- 2001-02-06 AT AT01902410T patent/ATE317261T1/de active
- 2001-02-06 CA CA002396209A patent/CA2396209C/en not_active Expired - Lifetime
- 2001-02-06 SK SK1144-2002A patent/SK287396B6/sk not_active IP Right Cessation
- 2001-02-06 RU RU2002124141/15A patent/RU2270680C2/ru not_active IP Right Cessation
- 2001-02-06 CZ CZ20022330A patent/CZ302368B6/cs not_active IP Right Cessation
- 2001-02-08 PE PE2001000141A patent/PE20011080A1/es not_active Application Discontinuation
- 2001-02-09 AR ARP010100585A patent/AR027394A1/es unknown
- 2001-02-09 CO CO01009904A patent/CO5271706A1/es not_active Application Discontinuation
-
2002
- 2002-06-18 IL IL150290A patent/IL150290A/en not_active IP Right Cessation
- 2002-06-28 ZA ZA200205238A patent/ZA200205238B/en unknown
- 2002-08-09 NO NO20023803A patent/NO328007B1/no not_active IP Right Cessation
-
2003
- 2003-02-24 HK HK03101379.6A patent/HK1049122B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hindmarch et al. | Psychopharmacological effects of sertraline in normal, healthy volunteers | |
| Lindberg et al. | Effect of a single-dose of olanzapine on sleep in healthy females and males | |
| US20130150434A1 (en) | Methods of using low-dose doxepin for the improvement of sleep | |
| NZ196048A (en) | Anti-depressant compositions with reduced induction of drowsiness-benzodiazepine tranquilliser/m-(chloro or fluoro)-t-butylaminopropiophenone | |
| CA2396209C (en) | The use of mirtazapine for the treatment of sleep disorders | |
| RU2268725C2 (ru) | Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств | |
| Schück et al. | Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers | |
| JPH0920666A (ja) | 成熟遅延および類似疾患の治療用医薬組成物 | |
| Mendelson | Pharmacotherapy of insomnia | |
| US20090197873A1 (en) | Compositions comprising alprazolam for treating primary insomnia and insomnia associate with anxiety states and process for preparing them | |
| Kerr et al. | The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers | |
| Middleton | Temazepam (Euhypnos®) and chlormethiazole: a comparative study in geriatric patients | |
| MXPA02006710A (es) | Uso de mirtazapina para el tratamiento de padecimientos de sueño | |
| TWI297607B (en) | The use of mirtazapine for the treatment of sleep disorders and pharmaceutical composition comprising mirtazapine | |
| Pinna et al. | Delirium in COVID patients: recommendations for assessment and treatment | |
| Velasco et al. | Effect of a new thienodiazepine (We-941) on sleep patterns of normal and insomniac subjects | |
| Fairweather et al. | The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. | |
| MEADOR-WOODRUFF et al. | SINGLE CASE STUDY: Profound Behavioral Toxicity due to Tricyclic Antidepressants | |
| Pollack et al. | Variables in the clinical evaluation of a hypnotic drug with a clinical evaluation of glutethimide | |
| Armstrong | Prevention of traveller's diarrhea with doxycycline. | |
| Kimball | Altered states of consciousness: Functional and organic brain syndromes | |
| Fink et al. | Electroencephalographic measures for pharmacodynamic analysis of psychoactive drugs in man | |
| Powles | Four perspectives on depression and the depressive illnesses. |